title: Outcome in breast molecular subtypes according to nodal status and surgical procedures.
abstract: BACKGROUND
  The purpose of our study was to evaluate the surgical treatment and outcome of breast cancer according to molecular subtypes.
  
  
  METHODS
  We identified 1,194 patients consecutively treated for primary breast cancer from 2004 to 2010. The type of surgery, pathological findings, local recurrence, and distant metastasis were evaluated for 5 molecular subtypes: luminal A and B, luminal HER2 (Human Epidermal Growth Factor Receptor 2), HER2 , and triple negative.
  
  
  RESULTS
  Breast-conserving surgery (BCS) was performed more frequently in luminal A (70.6%), triple-negative (66.2%), and luminal HER2 tumors (60.9%) (P < .001). A sentinel node biopsy was performed more frequently in luminal A (60%), and luminal HER2 (29.3%) types (P < .001). Among the 791 BCS, positive nodes were observed more often in HER2 (50%) and luminal B (44.9%) types (P = .0003). The number of local recurrences was higher in the node-negative luminal B subtype (3.4%).
  
  
  CONCLUSIONS
  Molecular subtypes exert an impact on BCS and nodal surgery rates. The local relapse rates are influenced by the molecular subtypes according to the nodal status.
authors: Department of Breast Surgery, Institut Gustave Roussy, Villejuif, France. chafika.mazouni@igr.fr
authors: Chafika
authors: C
authors: Mazouni
authors: Françoise
authors: F
authors: Rimareix
authors: Marie-Christine
authors: MC
authors: Mathieu
authors: Catherine
authors: C
authors: Uzan
authors: Céline
authors: C
authors: Bourgier
authors: Fabrice
authors: F
authors: André
authors: Suzette
authors: S
authors: Delaloge
authors: Jean-Rémi
authors: JR
authors: Garbay
mesh_terms: D000328:Adult; D001943:Breast Neoplasms / Q000378:metabolism* / Q000401:mortality / Q000473:pathology* / Q000601:surgery; D005260:Female; D006801:Humans; D008198:Lymph Nodes / Q000473:pathology*; D008207:Lymphatic Metastasis; D008408:Mastectomy; D015412:Mastectomy, Segmental; D009364:Neoplasm Recurrence, Local; D011379:Prognosis; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism*; D011960:Receptors, Estrogen / Q000378:metabolism*; D011980:Receptors, Progesterone / Q000378:metabolism*; D012189:Retrospective Studies; D021701:Sentinel Lymph Node Biopsy
chemical_list: D018719:Erb-b2 Receptor Tyrosine Kinases; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone